💊

Tecartus

brexucabtagene autoleucel

Lymphoma, Mantle-Cell

✅ Authorised Advanced therapy

✅

No active alerts

This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Mantle cell lymphoma Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Acute lymphoblastic leukaemia Tecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

⚠️ Patient safety

Official EMA page

https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus

📋 Authorisation

Marketing authorisation holder

Kite Pharma EU B.V.

Authorisation date

April 23, 2026

ATC code

L01X

Pharmacotherapeutic group

Antineoplastic agents

Active substance(s)

autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel)

Last updated by EMA: May 19, 2026